205 related articles for article (PubMed ID: 32228520)
1. Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.
Hardtstock F; Myers D; Li T; Cizova D; Maywald U; Wilke T; Griesinger F
BMC Cancer; 2020 Mar; 20(1):260. PubMed ID: 32228520
[TBL] [Abstract][Full Text] [Related]
2. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom.
Lester J; Escriu C; Khan S; Hudson E; Mansy T; Conn A; Chan S; Powell C; Brock J; Conibear J; Nelless L; Nayar V; Zhuo X; Durand A; Amin A; Martin P; Zhang X; Pawar V
BMC Cancer; 2021 May; 21(1):515. PubMed ID: 33962574
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
5. Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
Sheinson D; Wong WB; Wu N; Mansfield AS
Lung Cancer; 2020 May; 143():86-92. PubMed ID: 32276206
[TBL] [Abstract][Full Text] [Related]
6. Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
Stricker T; Jain N; Ma E; Yu E; Wang R; Schuldt R; Price R; Szado T; Sussell J; Ogale S; Lin V; Arrowsmith E; Slater D; Vaena D; Staszewski H; Fang B; Seneviratne L; Daniel D
Oncologist; 2024 Jun; 29(6):534-542. PubMed ID: 38417095
[TBL] [Abstract][Full Text] [Related]
7. Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study.
Molife C; Winfree KB; Bailey H; D'yachkova Y; Forshaw C; Kim S; Taipale KL; Puri T
Adv Ther; 2023 Jul; 40(7):3135-3168. PubMed ID: 37221352
[TBL] [Abstract][Full Text] [Related]
8. Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients.
Davies J; Martinec M; Coudert M; Delmar P; Crane G
Curr Med Res Opin; 2019 Mar; 35(3):535-542. PubMed ID: 30296185
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
Pan IW; Mallick R; Dhanda R; Nadler E
Lung Cancer; 2013 Dec; 82(3):469-76. PubMed ID: 24396885
[TBL] [Abstract][Full Text] [Related]
11. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
[TBL] [Abstract][Full Text] [Related]
12. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
Okamoto I; Morita S; Tashiro N; Imamura F; Inoue A; Seto T; Yamamoto N; Ohe Y; Nakagawa K; Fukuoka M
Lung Cancer; 2018 Mar; 117():14-19. PubMed ID: 29496250
[TBL] [Abstract][Full Text] [Related]
13. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
[TBL] [Abstract][Full Text] [Related]
14. Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
Fu P; Pennell NA; Sharma N; Yi Q; Dowlati A
Rev Recent Clin Trials; 2017; 12(1):51-58. PubMed ID: 27633965
[TBL] [Abstract][Full Text] [Related]
15. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
16. Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics.
John A; Shah RA; Wong WB; Schneider CE; Alexander M
Oncologist; 2020 Nov; 25(11):e1743-e1752. PubMed ID: 32627882
[TBL] [Abstract][Full Text] [Related]
17. Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
Schwartzberg L; Korytowsky B; Penrod JR; Zhang Y; Le TK; Batenchuk C; Krug L
Clin Lung Cancer; 2019 Jul; 20(4):287-296.e4. PubMed ID: 31130450
[TBL] [Abstract][Full Text] [Related]
18. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
[TBL] [Abstract][Full Text] [Related]
19. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
Moldaver D; Hurry M; Evans WK; Cheema PK; Sangha R; Burkes R; Melosky B; Tran D; Boehm D; Venkatesh J; Walisser S; Orava E; Grima D
Lung Cancer; 2020 Jan; 139():185-194. PubMed ID: 31812889
[TBL] [Abstract][Full Text] [Related]
20. Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases.
Griesinger F; Ramagopalan S; Cheung WY; Wilke T; Mueller S; Gupta A; O'Sullivan DE; Arora P; Brenner DR; Froelich C; Inskip J; Maywald U; Subbiah V
Cancer; 2024 Feb; 130(4):530-540. PubMed ID: 37933916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
